drugset

drugset / Trial / NCT00965497

Escitalopram (Lexapro) for Depression MS or ALS

NCT00965497 ↗

Phase 3 Completed 13 enrolled University of South Carolina

NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to see if escitalopram (Lexapro) improves symptoms of major depressive disorder in patients who have ALS or MS.

Timeline

Start: 2009-07
Primary completion: 2010-03
Completion: 2010-03

Publications

Background Cohen SR, Mount BM, Strobel MG, Bui F. The McGill Quality of Life Questionnaire: a measure of quality of life appropriate for people with advanced disease. A preliminary study of validity and acceptability. Palliat Med. 1995 Jul;9(3):207-19. doi: 10.1177/026921639500900306.
Background Ganzini L, Johnston WS, Hoffman WF. Correlates of suffering in amyotrophic lateral sclerosis. Neurology. 1999 Apr 22;52(7):1434-40. doi: 10.1212/wnl.52.7.1434.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Escitalopram	Small molecule	20 mg	—

Indications